AI Treatment Analysis

Powered by Agilisium Context AI — Precision Medicine Engine

FDA Black Box Warning — Clopidogrel (Plavix)

FDA Verified

WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE. The effectiveness of Plavix is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. Tests are available to identify patients who are CYP2C19 poor metabolizers. Consider use of another platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers.

Source: OpenFDA Drug Label API — GET /drug/label.json?search=openfda.generic_name:"clopidogrel"

Select Patient

Selected Patient

RK

Rajesh Kumar

58y · Male · B+

ID: PAT-DEMO001

Conditions

Type 2 Diabetes, Hypertension, Coronary Artery Disease

Medications

4 active

Allergies

Penicillin, Sulfonamides

Genomic Variants

3 flagged

Laboratory Results

Metabolic Panel

HbA1c
<7.08.9 %high
Creatinine
0.7-1.21.4 mg/dLhigh
eGFR
>6052 mL/minlow

Lipid Panel

LDL Cholesterol
<100142 mg/dLhigh
HDL Cholesterol
>4038 mg/dLlow

Analysis Parameters

Powered by GPT-4o · Agilisium Context AI